InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. More information coming soon.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 03/31/08 | Series C | 12.9M | Asset Management, Lanfear Capital, OrbiMed Advisors, Sears Capital Management, Sofinnova Ventures, Vivo Ventures | Unknown |
People
Larry Strauss (CFO)
Harold Selick (CEO)
George Shopp (Sr. Director of Preclinical & Toxicology)
David Brand (CEO, Founder, President)
Martin Freed (Board Member)
View more details about all 14 people at InteKrin Therapeutics
Competitors
Biodel:
Biodel has developed several therapeutic candidates for the treatment of diabetes and osteoporosis. All of Biodel's… See Company Profile »
News
InteKrin, a co. that fights diabetes and obesity, raises $23M
January 15, 2007 12:17 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now InteKrin Therapeutics, Inc., a Palo Alto company developing products to… Continue reading ⟩